{"id":16459,"date":"2022-03-08T17:29:45","date_gmt":"2022-03-08T11:59:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16459"},"modified":"2022-03-10T10:18:06","modified_gmt":"2022-03-10T04:48:06","slug":"pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto","title":{"rendered":"Lilly &#038; Boehringer\u2019s Jardiance; BMS Secures a Neoadjuvant Market for Opdivo; Amgen &#038; NHS Signs a Deal; Roche\u2019s Alzheimer Drug gantenerumab; Pfizer\u2019s RSV Vaccine; Civica\u2019s Insulin Biosimilars; Eli Lilly &#038; Incyte\u2019s JAK inhibitor Olumiant; Natco Pharma Launches Revlimid Generic"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a6b53613ba5e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a6b53613ba5e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#Eli_Lilly_Boehringer_Ingelheims_Jardiance_Giving_Competition_to_AstraZenecas_Farxiga_with_EU_Approval\" >Eli Lilly, Boehringer Ingelheim\u2019s Jardiance Giving Competition to AstraZeneca\u2019s Farxiga with EU Approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#BMS_Secures_a_Neoadjuvant_Market_for_Opdivo_in_NSCLC\" >BMS Secures a Neoadjuvant Market for Opdivo in NSCLC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#FDA_Grants_Breakthrough_Status_to_Pfizers_RSV_Vaccine\" >FDA Grants Breakthrough Status to Pfizer\u2019s RSV Vaccine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#Civica_Plans_to_Shake_Up_the_Insulin_Market_with_Low-cost_Biosimilars\" >Civica Plans to Shake Up the Insulin Market with Low-cost Biosimilars<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#Amgen_NHS_Strike_Deal_to_Enhance_Lumykras_Availability_in_the_UK\" >Amgen, NHS Strike Deal to Enhance Lumykras Availability in the UK<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#Roche_Begins_a_New_Four-Year_Study_of_the_Alzheimers_Drug_Gantenerumab\" >Roche Begins a New Four-Year Study of the Alzheimer&#8217;s Drug Gantenerumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#Olumiant_Benefits_Additive_to_Other_Drugs_in_people_With_Severe_COVID\" >Olumiant Benefits Additive to Other Drugs in people With Severe COVID&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\/#Natco_Pharma_Launches_First_Generic_Drug_of_Revlimid\" >Natco Pharma Launches First Generic Drug of Revlimid<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-boehringer-ingelheim-s-jardiance-giving-competition-to-astrazeneca-s-farxiga-with-eu-approval\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_Boehringer_Ingelheims_Jardiance_Giving_Competition_to_AstraZenecas_Farxiga_with_EU_Approval\"><\/span><strong>Eli Lilly, Boehringer Ingelheim\u2019s Jardiance Giving Competition to AstraZeneca\u2019s Farxiga with EU Approval<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Jardiance<\/strong>, the diabetes blockbuster from <strong>Eli Lilly and Boehringer Ingelheim<\/strong>, recently received a Heart Failure label expansion in the United States. Now, the drug is expanding into Europe, with a nod that might help it catch up to it\u2019s rival i.e. <strong>AstraZeneca&#8217;s SGLT2 Farxiga.<\/strong><\/p>\n\n\n\n<p>The EU made its decision based on the findings of <strong>Jardiance&#8217;s late-stage EMPEROR-Preserved study<\/strong>, which revealed that the medicine reduced the risk of cardiovascular death or heart failure hospitalization by <strong>21%<\/strong>. According to Boehringer, the drug&#8217;s benefit was found regardless of the patients&#8217; ejection fraction or diabetes status.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/jardiance-api-insights\"><strong>Jardiance&#8217;s<\/strong><\/a> label expansion should give it an advantage over <strong>AstraZeneca&#8217;s entrenched SGLT2 competitor Farxiga<\/strong>, known as <strong>Forxiga <\/strong>in Europe, which beat Jardiance to the cardiovascular punch back in 2020. Farxiga became the first drug in its class to receive Heart Failure approval in November of that year, with approval to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-hf-with-reduced-ejection-fraction-hfref-market\">HFrEF patients<\/a> with and without Type 2 diabetes. Aside from HFrEF, the drug is approved in Europe to treat Type 2 Diabetes and Chronic Kidney Disease.<\/p>\n\n\n\n<p>Jardiance sales had increased<strong> 17.2%<\/strong> to <strong>1.4 billion euros (USD 1.53 billion)<\/strong> by the middle of 2021, according to a half-year earnings report published in August by Boehringer Ingelheim. Jardiance sales in the United States totaled <strong>USD 1.49 billion<\/strong> for the full year. On the other hand, <strong>AstraZeneca\u2019s Farxiga<\/strong> is expected to generate around <strong>USD 3 billion<\/strong> by 2021.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BMS_Secures_a_Neoadjuvant_Market_for_Opdivo_in_NSCLC\"><\/span><strong>BMS Secures a Neoadjuvant Market for Opdivo in NSCLC<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Keytruda (pembrolizumab)<\/strong> has been the dominant PD-1\/PD-L1 drug in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-market\">NSCLC market<\/a>, owing primarily to its role in first-line therapy for more advanced cases, but competitors have been quicker to move into the neoadjuvant and adjuvant settings. While <strong>Bristol-Myers Squibb&#8217;s Opdivo<\/strong> has been the second fiddle for years, it now has a chance to shine on its own.<\/p>\n\n\n\n<p><strong>Opdivo (nivolumab)<\/strong> is the first and only cancer immunotherapy to be approved in the United States for the neoadjuvant treatment of NSCLC, which is used to shrink tumors before they are surgically removed. The goal of surgery in these <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight\">NSCLC patients<\/a> is curative, but between one-third and half will experience recurrence and require additional treatment.<\/p>\n\n\n\n<p>The approval was based on the findings of <strong>Phase 3 CheckMate-816 study<\/strong>, which found that the combination of Opdivo and pre-surgery chemotherapy significantly improved event-free survival, with a <strong>37%<\/strong> reduction in the risk of progression, recurrence, or death when compared to chemo alone. The benefit was seen regardless of PD-L1 levels, making Opdivo an option for all people with resectable NSCLC who do not require testing.<\/p>\n\n\n\n<p>Opdivo was approved as part of the <strong>FDA&#8217;s Real-Time Oncology Review (RTOR) pilot program<\/strong>, which aims to expedite access to new treatments. It was also conducted as part of Project Orbis, a collaboration between the FDA and regulators in Australia, Canada, and the United Kingdom, where Opdivo is still being evaluated.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Grants_Breakthrough_Status_to_Pfizers_RSV_Vaccine\"><\/span><strong>FDA Grants Breakthrough Status to Pfizer\u2019s RSV Vaccine<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer has received FDA breakthrough therapy designation to its <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-pipeline-insight\">respiratory syncytial virus (RSV) vaccine<\/a> candidate, <strong>PF-06928316 (RSVpreF)<\/strong>. The vaccine is developed to prevent RSV-associated lower respiratory tract illness in infants from birth to 6 months by active immunization of pregnant women.&nbsp;<\/p>\n\n\n\n<p>The FDA decision is based on the results of phase 2b proof-of-concept study of <strong>RSVpreF (NCT04032093) <\/strong>in a double-blinded, global, placebo-controlled study in healthy pregnant women aged 18 to 49 years and their infants. RSVpreF comprises two preF proteins desired to improve safety against <strong>RSV A and B<\/strong>. Pfizer is expected to publish the trial results in the coming months. Earlier in September 2021, Pfizer announced the initiation of another phase 3 clinical trial to evaluate the efficacy, immunogenicity, and safety of a single dose of <strong>RSVpreF <\/strong>in individuals aged 60 years and older.<\/p>\n\n\n\n<p>Respiratory Syncytial Virus is a contagious virus that can affect the lungs and breathing passages. It can be potentially life-threatening for young infants, the immunocompromised, and older adults. Moreover, in the United States, Respiratory Syncytial Virus leads to nearly <strong>50,000 hospitalizations<\/strong> in children under the age of 5 years. As of now, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\"><strong>Respiratory Syncytial Virus therapeutics market<\/strong><\/a> does not have any vaccine, and only supportive care is available to prevent the condition. The positive result and approval of the emerging therapies including <strong>PF-06928316<\/strong> are expected to significantly improve the treatment outcome for the affected individual.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Civica_Plans_to_Shake_Up_the_Insulin_Market_with_Low-cost_Biosimilars\"><\/span><strong>Civica Plans to Shake Up the Insulin Market with Low-cost Biosimilars<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Insulin affordability is one of the major challenges in the healthcare segment. To overcome this issue, Civica has announced plans to manufacture and distribute insulins at a lower price compared to the existing market prices. Civica is a nonprofit generic pharmaceutical company with its insulin initiative aimed to push the affordability and accessibility of insulin in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/us-healthcare-outlook-report\">US healthcare market<\/a>. The Civica has collaborated with the Juvenile Diabetes research foundation (JDRF), a leading global type 1 diabetes (T1D) research and advocacy organization.&nbsp;<\/p>\n\n\n\n<p>Civica is intended to manufacture 3 <a href=\"https:\/\/www.delveinsight.com\/blog\/biosimilar-market-outlook\">insulin biosimilars.<\/a> The first is <strong>Sanofi\u2019s Lantus (<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/insulin-glargine-biosimilar-insight\"><strong>insulin glargine<\/strong><\/a><strong>)<\/strong> which is a long-acting insulin biosimilar. The other two insulin include rapid-acting insulins, one of <strong>Novo Nordisk\u2019s Novolog (insulin aspart)<\/strong> and <strong>Eli Lilly\u2019s Humalog (insulin lispro)<\/strong>. The insulins will be available both in vials and prefilled pens. Civica intends to charge no more than $30 per vial and no more than $55 for a box of five pen cartridges. Civica is expected to complete the clinical trials, file the necessary applications for FDA approval and the availability of the first insulin (glargine) in the US by 2024. Additionally, Civica entered into an agreement with <strong>GeneSys Biologics<\/strong> for the co-development of three insulin biosimilars.&nbsp;<\/p>\n\n\n\n<p>Diabetes is a chronic condition that affects a significant portion of the population globally. As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-market\"><strong>Diabetes Market<\/strong><\/a>\u201d report, in the United States, around 34 million people are affected with diabetes which is nearly 10.5% of the total population. Over time Diabetes can lead to significant damage to various body parts such as the heart, eyes, kidneys, blood vessels, and nerves. Insulin therapy is crucial for <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-pipeline-insight\">diabetes treatment<\/a>. Currently, insulin affordability is one of the major challenges. However, the approval of the low-cost insulins by the Civica is expected to significantly improve the affordability of the insulins and the treatment outcome for the uninsured or underinsured person.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Amgen_NHS_Strike_Deal_to_Enhance_Lumykras_Availability_in_the_UK\"><\/span><strong>Amgen, NHS Strike Deal to Enhance Lumykras Availability in the UK<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>National Health Service (NHS) struck a deal with Amgen with regard to the company\u2019s hit <strong>lung-cancer<\/strong> drug <strong>Lumykras<\/strong>, in order to make it more available to the affected people.<\/p>\n\n\n\n<p>The agreement accounted for Lumykras administration to <strong>600 patients.<\/strong> This deal comes after <strong>100 patients<\/strong> were granted access to the drug in September of last year under <strong>Project Orbis.<\/strong> This project was considered a collaborative effort between the United States, Canada, Australia, the U.K. drug regulators, and many other countries to speed up the <a href=\"https:\/\/www.delveinsight.com\/blog\/oncological-drugs-to-be-launch-in-2022\">approval for promising cancer treatments<\/a>.&nbsp;<\/p>\n\n\n\n<p>This treatment comes as a second project under <strong>Orbis<\/strong>, as the first one was <strong>AstraZeneca\u2019s Tagrisso<\/strong>, another <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight\">lung cancer treatment drug<\/a>. This project helped in giving a green flag to a variety of cancer drugs. The drug is marketed with the name of Lumakras in the US. Last May, Lumykras scored FDA approval for a specific <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-epidemiology-forecast\">type of non-small cell lung cancer<\/a> that was earlier considered to be \u201cundruggable.\u201d It is used for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-mutant-cancer-pipeline-insight\">treatment of KRAS G12C mutation<\/a>, also known as the <strong>\u201cdeath star,\u201d<\/strong> for its shape and resistance to treatment. This type is observed in almost<strong> 13% <\/strong>of NSCLC patients. The second-line treatment can be administered to patients who didn\u2019t respond to chemotherapy previously and have fewer side effects. Another advantageous factor is its ease of administration and it can be taken in tablet form.<\/p>\n\n\n\n<p>\u201cIt is very exciting to see this ground-breaking treatment coming into use after 40 years of research on this important target,\u201d the NHS\u2019s clinical director for cancer, Peter Johnson, said in a release.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche_Begins_a_New_Four-Year_Study_of_the_Alzheimers_Drug_Gantenerumab\"><\/span><strong>Roche Begins a New Four-Year Study of the Alzheimer&#8217;s Drug Gantenerumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The pharma giant &#8211; Roche is looking forward to a four-year Phase III study of its Alzheimer&#8217;s drug <strong>gantenerumab. <\/strong>This new study will be a placebo-controlled <strong>SKYLINE study<\/strong> with <strong>1,250 participants<\/strong> aged between <strong>60 to 80 years<\/strong>, with the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\">earliest biological signs of Alzheimer\u2019s<\/a> but no cognitive impairment. The focus of this study is to see whether the anti-amyloid antibody can slow disease progression over a four-year follow-up period.<\/p>\n\n\n\n<p>The drug received a breakthrough therapy designation from the FDA. The Swiss pharma&#8217;s Genentech unit is reported to initiate two pivotal trials of gantenerumab in the second half of the year. These two studies namely <strong>Graduate 1 and 2, <\/strong>constitutes for more than <strong>2,000 patients<\/strong> with initial symptom appearance of Alzheimer&#8217;s Disease. The study is also supposed to test the monoclonal antibody in patients who either don&#8217;t have Alzheimer&#8217;s but are at risk or are in the earliest stages of the memory-robbing disease.<\/p>\n\n\n\n<p>The past record of the drug isn\u2019t much encouraging, as gantenerumab has previously failed a Phase III <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">trial in Alzheimer\u2019s patients<\/a> who showed early signs of cognitive impairment. However, the willingness of Roche&nbsp; to launch another Phase 3 trial indicates that&nbsp; it is willing to play the long game, and bet more money on the drug, hoping that the role of anti-amyloid drugs will become more clear in the coming years.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Olumiant_Benefits_Additive_to_Other_Drugs_in_people_With_Severe_COVID\"><\/span><strong>Olumiant Benefits Additive to Other Drugs in people With Severe COVID&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to new findings from the <strong>UK RECOVERY trial<\/strong>, <strong>Eli Lilly<\/strong> and <strong>Incyte\u2019s JAK inhibitor Olumiant <\/strong>reduced the death risk by 13% in hospitalized COVID-19 patients when added to other drugs. The benefit came when <strong>Olumiant <\/strong>(<strong>baricitinib<\/strong>) was added to two other anti-inflammatory drugs (<strong>steroid dexamethasone<\/strong> and <strong>Roche\u2019s IL-6 inhibitor Actemra\/RoActemra (tocilizumab<\/strong>)),&nbsp; that have also been shown to boost the survival in severe COVID-19 cases, as well as <strong>Gilead\u2019s <\/strong>antiviral <strong>Veklury <\/strong>(<strong>remdesivir<\/strong>).<\/p>\n\n\n\n<p>According to the researchers, overall, <strong>513<\/strong> of <strong>4,148<\/strong> patients allocated to baricitinib versus <strong>546<\/strong> of <strong>4,008 <\/strong>patients assigned to usual care died within 28 days. The finding is significant as giving the drug combined with the other therapies could save more lives in people with severe <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19<\/strong><\/a>. Olumiant could also be an alternative for areas where access to other drugs is limited.<\/p>\n\n\n\n<p>Patients consuming baricitinib were also more likely to be discharged alive within 28 days. They were less likely to require mechanical ventilation, and there was no evidence of increased risk of infections or blood clots, all of which are possible side effects of Olumiant therapy.<\/p>\n\n\n\n<p>The findings support Olumiant&#8217;s earlier findings in COVID-19, which showed a significant impact on mortality and led to the drug&#8217;s placement on the World Health Organization&#8217;s list of approved COVID-19 therapies earlier this year. There was limited information about the drug&#8217;s use in addition to <strong>Actemra <\/strong>in the earlier trials. While vaccination appears to be keeping the COVID 19 pandemic under control in the <strong>UK <\/strong>and many other countries, many cases remain, and the death toll continues to rise. Over the last week, there have been an average of <strong>60,000<\/strong> new points and <strong>159<\/strong> daily fatalities in the United Kingdom.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Natco_Pharma_Launches_First_Generic_Drug_of_Revlimid\"><\/span><strong>Natco Pharma Launches First Generic Drug of Revlimid<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Natco Pharma<\/strong>, along with its marketing partner <strong>Arrow International<\/strong> &#8211; an affiliate of Israeli-drug maker T<strong>eva Pharmaceutical Industries<\/strong>, announced the first generic version of <strong>Celgene&#8217;s <\/strong>(now acquired by <strong>Bristol Myers Squibb<\/strong>) top-selling cancer drug <strong>Revlimid <\/strong>(<strong>lenalidomide<\/strong> <strong>capsules<\/strong>) in the United States market.<\/p>\n\n\n\n<p>According to <strong>IQVIA <\/strong>data, <strong>Revlimid <\/strong>had annual sales of <strong>$2.3 billion<\/strong> as of <strong>December 2021. <\/strong>The generic version of Revlimid will be accessible in <strong>5mg, 10mg, 15mg<\/strong>, and <strong>25 mg<\/strong> strengths. The announcement came after market hours. The Shares of Natco Pharma were <strong>2.98%<\/strong> to close at <strong>Rs 844.30<\/strong> on Bombay Stock Exchange (BSE) on Monday; the benchmark Sensex fell <strong>2.74%<\/strong> to end at <strong>52,842.75<\/strong> points.<\/p>\n\n\n\n<p>Natco, along with Arrow International, previously settled the <strong>Paragraph IV litigation<\/strong> in <strong>2015 <\/strong>related to the Revlimid with Celgene, which is now a part of Bristol-Myers Squibb. Adults are prescribed lenalidomide capsules to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\"><strong>multiple myeloma<\/strong><\/a><strong> <\/strong>combined with <strong>dexamethasone<\/strong>, certain <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-market\"><strong>myelodysplastic syndromes<\/strong><\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/mantle-cell-lymphoma-market\"><strong>mantle cell lymphoma<\/strong><\/a><strong> <\/strong>after specific previous treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly, Boehringer Ingelheim\u2019s Jardiance Giving Competition to AstraZeneca\u2019s Farxiga with EU Approval Jardiance, the diabetes blockbuster from Eli Lilly and Boehringer Ingelheim, recently received a Heart Failure label expansion in the United States. Now, the drug is expanding into Europe, with a nod that might help it catch up to it\u2019s rival i.e. AstraZeneca&#8217;s [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":16465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[349,420,639],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-16459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-latest-pharma-news","tag-news","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pharma News and Updates | Lilly, Amgen, Roche, Pfizer, Civica, Nacto<\/title>\n<meta name=\"description\" content=\"Lilly &amp; Boehringer\u2019s Jardiance; Roche\u2019s gantenerumab; Pfizer\u2019s RSV Vaccine; Civica\u2019s Insulin Biosimilars; Natco;&#039;s Revlimid Generic\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News and Updates | Lilly, Amgen, Roche, Pfizer, Civica, Nacto\" \/>\n<meta property=\"og:description\" content=\"Lilly &amp; Boehringer\u2019s Jardiance; Roche\u2019s gantenerumab; Pfizer\u2019s RSV Vaccine; Civica\u2019s Insulin Biosimilars; Natco;&#039;s Revlimid Generic\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-08T11:59:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T04:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/08174206\/Latest-Pharma-News-and-Updates-for-Lilly-Amgen-Roche-Pfizer-Civica-Nacto.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News and Updates | Lilly, Amgen, Roche, Pfizer, Civica, Nacto","description":"Lilly & Boehringer\u2019s Jardiance; Roche\u2019s gantenerumab; Pfizer\u2019s RSV Vaccine; Civica\u2019s Insulin Biosimilars; Natco;'s Revlimid Generic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto","og_locale":"en_US","og_type":"article","og_title":"Pharma News and Updates | Lilly, Amgen, Roche, Pfizer, Civica, Nacto","og_description":"Lilly & Boehringer\u2019s Jardiance; Roche\u2019s gantenerumab; Pfizer\u2019s RSV Vaccine; Civica\u2019s Insulin Biosimilars; Natco;'s Revlimid Generic","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-03-08T11:59:45+00:00","article_modified_time":"2022-03-10T04:48:06+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/08174206\/Latest-Pharma-News-and-Updates-for-Lilly-Amgen-Roche-Pfizer-Civica-Nacto.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto"},"author":{"name":"DelveInsight","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"headline":"Lilly &#038; Boehringer\u2019s Jardiance; BMS Secures a Neoadjuvant Market for Opdivo; Amgen &#038; NHS Signs a Deal; Roche\u2019s Alzheimer Drug gantenerumab; Pfizer\u2019s RSV Vaccine; Civica\u2019s Insulin Biosimilars; Eli Lilly &#038; Incyte\u2019s JAK inhibitor Olumiant; Natco Pharma Launches Revlimid Generic","datePublished":"2022-03-08T11:59:45+00:00","dateModified":"2022-03-10T04:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto"},"wordCount":2034,"commentCount":0,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/08174206\/Latest-Pharma-News-and-Updates-for-Lilly-Amgen-Roche-Pfizer-Civica-Nacto.png","keywords":["Latest pharma news","news","pharma news"],"articleSection":["Notizia - Recent Pharma, Healthcare and Biotech Happenings"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto","name":"Pharma News and Updates | Lilly, Amgen, Roche, Pfizer, Civica, Nacto","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/08174206\/Latest-Pharma-News-and-Updates-for-Lilly-Amgen-Roche-Pfizer-Civica-Nacto.png","datePublished":"2022-03-08T11:59:45+00:00","dateModified":"2022-03-10T04:48:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Lilly & Boehringer\u2019s Jardiance; Roche\u2019s gantenerumab; Pfizer\u2019s RSV Vaccine; Civica\u2019s Insulin Biosimilars; Natco;'s Revlimid Generic","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-lilly-bms-amgen-roche-pfizer-civica-nacto#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/08174206\/Latest-Pharma-News-and-Updates-for-Lilly-Amgen-Roche-Pfizer-Civica-Nacto.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/08174206\/Latest-Pharma-News-and-Updates-for-Lilly-Amgen-Roche-Pfizer-Civica-Nacto.png","width":772,"height":482,"caption":"Latest Pharma News and Updates for Lilly Amgen Roche Pfizer Civica Nacto"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/08174206\/Latest-Pharma-News-and-Updates-for-Lilly-Amgen-Roche-Pfizer-Civica-Nacto-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Mar 8, 2022","modified":"Updated on Mar 10, 2022"},"absolute_dates_time":{"created":"Posted on Mar 8, 2022 5:29 pm","modified":"Updated on Mar 10, 2022 10:18 am"},"featured_img_caption":"Latest Pharma News and Updates for Lilly Amgen Roche Pfizer Civica Nacto","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16459"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16459\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16459"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16459"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}